1. Volume 74, Issue 4, Pages 432-441 (October 2018)
Duration of Androgen Deprivation Therapy in High-risk Prostate Cancer: A Randomized Phase III Trial 
Abdenour Nabid, Nathalie Carrier, André-Guy Martin, Jean-Paul Bahary, Céline Lemaire, Sylvie Vass, Boris Bahoric, Robert Archambault, François Vincent, Redouane Bettahar, Marie Duclos, Marie-Pierre Garant, Luis Souhami 
European Urology 
Volume 74, Issue 4, Pages (October 2018)
DOI: /j.eururo
Copyright © 2018 European Association of Urology Terms and Conditions

2. Fig. 1 Enrollment and follow-up of study patients.
AA=anti-androgen; ADT=androgen deprivation therapy; Gy=Gray; LHRHa=luteinizing hormone-releasing hormone agonist; RT=radiotherapy.
European Urology  , DOI: ( /j.eururo )
Copyright © 2018 European Association of Urology Terms and Conditions

3. Fig. 2
Survival and biochemical failure rates between long arm (36 mo) and short arm (18 mo).
HR=hazard ratio with 95% confidence intervals.
HR compared between 36 mo and 18 mo.
European Urology  , DOI: ( /j.eururo )
Copyright © 2018 European Association of Urology Terms and Conditions

4. Fig. 3
Mean scores on quality of life assessment scales or items and time to normal testosterone level recovery. The mean scores were presented for global quality of life (A) (0 indicate no QoL and 100 high QoL), and sexual activity (B) (0 indicate no sexual activity and 100 high sexual activity). Other items: (C) interest in sex (0 indicate no interest and 100 high interest), (D) hot flushes (0 indicate no symptoms and 100 severe symptoms), (E) enjoyable sex (0 indicate no enjoyable and 100 high enjoyable). (F) Time to normal testosterone recovery. A p value<0.01 was considered statistically significant to account for multiple comparisons and a difference between groups in mean scores of ≥10 points as clinically relevant.
CI=confidence interval; QoL=quality of life.
European Urology  , DOI: ( /j.eururo )
Copyright © 2018 European Association of Urology Terms and Conditions